MARK MARTINDALE: Open Payments
NPI 1508416785 · COEUR D ALENE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,383 in 73 payments from 19 companies in 2025. Trend: 2023 $490 · 2024 $1,208 · 2025 $1,383
Food & beverage: $1,383
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $289 |
| AstraZeneca Pharmaceuticals LP | 9 | $180 |
| Axsome Therapeutics, Inc. | 8 | $171 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $96 |
| Otsuka America Pharmaceutical, Inc. | 4 | $84 |
| Alkermes, Inc. | 4 | $78 |
| Lilly USA, LLC | 4 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| Corcept Therapeutics | 3 | $57 |
| Novo Nordisk Inc | 3 | $54 |
Products named: UBRELVY, Auvelity, REXULTI, AIRSUPRA, VRAYLAR, CAPLYTA, LYBALVI, FARXIGA.
Industry payments across ID — which companies pay providers there.
